Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Braz. oral res. (Online) ; 37: e050, 2023. tab, graf
Artigo em Inglês | LILACS-Express | LILACS, BBO | ID: biblio-1439744

RESUMO

Abstract The aim of this study was to describe the prevalence, clinicopathological, and prognostic features of acinic cell carcinoma (AciCC) of the oral and maxillofacial region. AciCC cases were retrospectively retrieved from 11 pathology centers of three different countries. Medical records were examined to extract demographic, clinical, pathologic, and follow-up information. A total of 75 cases were included. Females (65.33%) with a mean age of 45.51 years were mostly affected. The lesions usually presented as an asymptomatic (64.28%) nodule (95.66%) in the parotid gland (70.68%). The association of two histopathological patterns was the most common finding (48.93%) and the tumors presented mainly conventional histopathological grades (86.11%). Surgical treatment was performed in the majority of the cases (59.19%). Local recurrence was observed in 20% of the informed cases, regional metastasis in 30.43%, and distant metastasis in 12.50%. The statistical analysis showed that the cases with a solid histopathological pattern (p=0.01), high-grade transformation (p=0.008), recurrence (p=0.007), and regional metastasis (p=0.03) were associated with poor survival. In conclusion, high histopathological transformation, presence of nodal metastasis, and recurrence were prognostic factors for AciCC of the oral and maxillofacial region.

2.
Rev. Col. Bras. Cir ; 46(2): e2094, 2019. tab, graf
Artigo em Português | LILACS | ID: biblio-1003087

RESUMO

RESUMO Objetivo: determinar a expressão de neurotrofinas e seus receptores tirosina quinases em pacientes com osteossarcoma (OS) e sua correlação com desfechos clínicos. Métodos: biópsias de tumores primários de pacientes com OS tratados em uma única instituição, consecutivamente, entre 2002 e 2015, foram analisados através de imuno-histoquímica para expressão de receptores de tirosina quinase A e B (TrKA e TrKB), fator de crescimento neural (NGF) e fator neurotrófico derivado do cérebro (BDNF). De forma independente, dois patologistas classificaram os marcadores de imuno-histoquímica como negativos (negativos e focais fracos) ou positivos (moderado focal/difuso ou forte focal/difuso). Resultados: foram analisados dados de 19 pacientes (10 do sexo feminino e 9 do masculino) com mediana de idade de 12 anos (5 a 17,3 anos). Dos tumores, 83,3% estavam localizados em membros inferiores e 63,2% dos pacientes eram metastáticos ao diagnóstico. A sobrevida global em cinco anos foi de 55,3%. BDNF foi positivo em 16 pacientes (84%) e NGF em 14 pacientes (73%). TrKA e TrKB apresentaram coloração positiva em quatro (21,1%) e oito (42,1%) pacientes, respectivamente. A análise de sobrevida não demonstrou diferença significativa entre receptores TrK e neurotrofinas. Conclusão: amostras de OS primário expressam neurotrofinas e receptores TrK através de imuno-histoquímica. Estudos futuros podem auxiliar na identificação do papel das mesmas na patogênese do OS e determinar se há possível correlação prognóstica.


ABSTRACT Objective: to determine the expression of neurotrophins and their tyrosine-kinase receptors in patients with osteosarcoma (OS) and their correlation with clinical outcomes. Methods: we applied immunohistochemistry to biopsy specimens of patients consecutively treated for primary OS at a single institution between 2002 and 2015, analyzing them for expression receptors of tyrosine kinase A and B (TrKA and TrKB), neural growth factor (NGF) and brain derived neurotrophic factor (BDNF). Independently, two pathologists classified the immunohistochemical markers as negative (negative or weak focal) or positive (moderate focal/diffuse or strong focal/diffuse). Results: we analyzed data from 19 patients (10 females and 9 males), with median age of 12 years (5 to 17.3). Tumors' location were 83.3% in the lower limbs, and 63.2% of patients had metastases at diagnosis. Five-year overall survival was 55.3%. BDNF was positive in 16 patients (84%) and NGF in 14 (73%). TrKA and TrKB presented positive staining in four (21,1%) and eight (42,1%) patients, respectively. Survival analysis showed no significant difference between TrK receptors and neurotrophins. Conclusion: primary OS samples express neurotrophins and TrK receptors by immunohistochemistry. Future studies should explore their role in OS pathogenesis and determine their prognostic significance in larger cohorts.


Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Neoplasias Ósseas/patologia , Osteossarcoma/patologia , Fator Neurotrófico Derivado do Encéfalo/análise , Receptor trkA/análise , Receptor trkB/análise , Fatores de Crescimento Neural/análise , Valores de Referência , Neoplasias Ósseas/mortalidade , Imuno-Histoquímica , Biomarcadores Tumorais , Osteossarcoma/mortalidade , Fatores de Risco , Estatísticas não Paramétricas , Estimativa de Kaplan-Meier
3.
Rev. gastroenterol. Perú ; 27(1): 47-56, ener.-mar. 2007. tab, graf
Artigo em Espanhol | LILACS, LIPECS | ID: lil-533809

RESUMO

Se realizó el presente estudio descriptivo retrospectivo y longitudinal para determinar el perfil epidemiológico de los pacientes infectados por virus de hepatitis C con hepatitis crónica, así como la evaluación de sus criterios de legibilidad para recibir tratamiento con Interferón Pegilado más Ribavirina y su respuesta virológica temprana al tratamiento. Se estudiaron 20 pacientes atendidos en el Servicio de Gastroenterología del Hospital Carlos Seguín Escobedo de EsSalud entre los años 2004 y 2006. El diagnóstico de infección por HVC se confirmó mediante la detección de DNA viral mediante PCR, y de la carga viral mediante el conteo de número de copias. Se determinaron los criterios de legibilidad para tratamiento antiviral; se empleó además el score METAVIR para determinar la presencia de fibrosis hepática. Luego de 12 semanas de tratamiento se evaluó a los pacientes que cumplieron criterios de elegibilidad y que accedieron al tratamiento y se evaluó su efectividad mediante una nueva determinación de la carga viral. Hubo más pacientes mujeres (15; 75 por ciento) que varones (5; 25 por ciento), con edades entre 50 y 59 años. El antecedente de riesgo más frecuente fue transfusión sanguínea (45 por ciento), cirugía (35 por ciento), y accidentes de trabajo (10 por ciento). Los valores de parámetros hematológicos, renal y hormonal estuvieron dentro de límites normales, los parámetros de función hepática (bilirrubinas, aminotransferasas, fosfatasa alcalina y gamaglutamil transpeptidasa) estuvieron por encima de lo normal; la carga viral al momento del diagnóstico fue en promedio de 580 mil copias (entre 4100 a 2 millones de copias). Los genotipos virales más frecuentes fueron 1a y 1b. Hasta 40 por ciento de pacientes no tuvieron criterios de elegibilidad para recibir tratamiento antiviral. Sólo 9 a 12 pacientes que tuvieron criterios de tratamiento lo recibieron (75 por ciento), en 6 de ellos se evaluó la respuesta virológica temprana y de ellos...


The present descriptive, retrospective and longitudinal study was designed todetermine the epidemic profile of patients infected by hepatitis C virus and chronic hepatitis, as well as to describe the eligibility criteria for treatment with pegilated interferon plus ribavirina and its early virological answer to the treatment. We studied 20 patients treated at Gastroenterology Service of Carlos Seguín Escobedo Hospital of EsSalud between 2004 and 2006. The diagnosis of HVC infection was confirmed by detection of viral RNA with PCR, and the viral load by counting number of RNA copies. The eligibility criteria for antiviral treatment were determined, and also the METAVIR score to determine hepatic fibrosis. After 12 weeks of treatment the patients with eligibility criteria and received treatment were evaluated, and theeffectivity of treatment was evaluated with a new determination of viral load.There were more female (15; 75 per cent) than male patients (5; 25 per cent), with ages between 50 and 59 years. The more frequent risk antecedent was blood transfusion (45 per cent), surgery (35 per cent), and traffic accident (10 per cent). The hematological, hepatic, renal and hormonal parameters were in normal range; and the viral load at the moment of diagnosis was of 580 thousand copies mean (between 4100 to 2 millions copies). The most frequent viral genotypes were 1a and 1b. Up to 40 per cent of patients did not fulfilled eligibility criteria for treatment. Nine of 12 patients with eligibility criteria received treatment (75 per cent), 6of them were evaluated for early virologc response and of them 100,0 per cent had an early virologic response with decrease of post-therapeutic viral load in all but one cases until non-detectable levels. In conclusion our study described the profile of patients infected by HCV with chronic hepatitis in gastroenterology ward of our hospital, and it has been determined that is suggestive that antiviral treatment is highly...


Assuntos
Humanos , Masculino , Adulto , Pessoa de Meia-Idade , Feminino , Antivirais , Carga Viral , Hepacivirus , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/terapia , Interferons/uso terapêutico , Ribavirina/uso terapêutico , Epidemiologia Descritiva , Estudos Longitudinais , Estudos Retrospectivos
4.
Rev. bras. cancerol ; 44(1): 51-6, jan.-mar. 1998. ilus
Artigo em Inglês | LILACS | ID: lil-218990

RESUMO

É relatado um caso de angiossarcoma primário de baço em um homem de 29 anos, fazendo-se a revisäo dos achados clínicos, diagnóstico anatomopatológico, tratamento e prognóstico. Angiossarcomas correspondem a menos de 1 porcento dos sarcomas de tecidos moles, e somente uma pequena fraçäo surge no baço. Esses tumores freqüentemente apresentam-se como um desafio diagnóstico para o patologista, tendo em vista as variaçöes na histologia, e o desenvolvimento de novos marcadores em painéis de imuno histoquímica, como o CD31, ajudam a descartar outros diagnósticos. Devido à raridade desse tumor näo existe um consenso em relaçäo ao tratamento quimioterápico e, via de regra, o prognóstico é ruim.


Assuntos
Humanos , Masculino , Adulto , Hemangiossarcoma/diagnóstico , Hemangiossarcoma/tratamento farmacológico , Hemangiossarcoma/patologia , Neoplasias Esplênicas/diagnóstico , Neoplasias Esplênicas/patologia , Neoplasias Esplênicas/tratamento farmacológico , Imuno-Histoquímica , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA